acute-myeloid-leukemia

Documents about acute-myeloid-leukemia

• Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients#838093ClinicalTrials.gov
• Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients#854235ClinicalTrials.gov
• Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant#856670ClinicalTrials.gov
• Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia#880944ClinicalTrials.gov
• Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant#909605ClinicalTrials.gov
• Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy#913843ClinicalTrials.gov
• Interpretable Multi-Instance Learning Enables Early Prediction of Key Molecular Alterations from Routine Flow Cytometry in Acute Myeloid Leukemia#1012985arXiv (All)
• A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)#1031778ClinicalTrials.gov
• A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia#1039227IRIS
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation#803898ClinicalTrials.gov
• Ascorbic Acid Levels in MDS, AML, and CMML Patients#827873ClinicalTrials.gov
• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)#886540ClinicalTrials.gov
• Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae#812351ClinicalTrials.gov
• Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia#908599ClinicalTrials.gov
• Bone Marrow Transplant in Treating Patients With Hematologic Cancers#980940ClinicalTrials.gov
• my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults#886876ClinicalTrials.gov
• NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)#806317ClinicalTrials.gov
• National Longitudinal Cohort of Hematological Diseases#806657ClinicalTrials.gov
• Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation#873879ClinicalTrials.gov
• A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML#895372ClinicalTrials.gov
• Effects of Allium roseum L. extracts on the proliferation and the differentiation of the acute myeloid leukemia cell line U937#20679HAL (France)
• Integrated analysis of programmed cell death-related genes identifies CORO1A as an apoptosis-associated gene in acute myeloid leukemia.#196059NCBI PubMed Central
• Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT#201778ClinicalTrials.gov
• Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML#321695ClinicalTrials.gov
• A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies#343818ClinicalTrials.gov
• Integration of transcriptomic data reveals lipid metabolic heterogeneity and identifies GSTO1 as a therapeutic target in acute myeloid leukemia.#371415NCBI PubMed Central
• Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism#389971S-Space: Seoul National University
• Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia#485163Europe PMC
• Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment#801000ClinicalTrials.gov
• Study of the Predictive Marker FLT in Patients Suffering From AML#827982ClinicalTrials.gov
• A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS#901357ClinicalTrials.gov
• RN-Led Palliative and Supportive Care Intervention#910301ClinicalTrials.gov
• Avapritinib in CBF-AML With KIT Mutations#912807ClinicalTrials.gov
• Interpretable Multi-Instance Learning Enables Early Prediction of Key Molecular Alterations from Routine Flow Cytometry in Acute Myeloid Leukemia#965416arXiv CS
• Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS#1045831ClinicalTrials.gov
• Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)#826785ClinicalTrials.gov
• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia#801882ClinicalTrials.gov
• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies#877911ClinicalTrials.gov
• The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation#848162ClinicalTrials.gov
• Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies#864955ClinicalTrials.gov
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors#868281ClinicalTrials.gov
• CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant#889432ClinicalTrials.gov
• T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies#992810ClinicalTrials.gov
• Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.#916522ClinicalTrials.gov
• Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome#884985ClinicalTrials.gov
• Predicting the toxicity-efficacy ratio of venetoclax in real-world patients#153509HAL (France)
• The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety#242042IRIS
• Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS#812611ClinicalTrials.gov
• A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies#829364ClinicalTrials.gov
• BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS#864243ClinicalTrials.gov